<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05097547</url>
  </required_header>
  <id_info>
    <org_study_id>HSR210335</org_study_id>
    <secondary_id>17803</secondary_id>
    <nct_id>NCT05097547</nct_id>
  </id_info>
  <brief_title>Contingency Management for Stimulant Use Disorders</brief_title>
  <official_title>Contingency Management for Stimulant Use Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The invetigators' objective is to implement Medication Assisted Treatment (MAT) and&#xD;
      contingency management in patients affected by co-occurring opioid use disorder and stimulant&#xD;
      use disorder. Participants will continue to receive standard of care for their opioid use&#xD;
      disorder via MAT at our Outpatient Based Opioid Treatment (OBOT) Clinic. Participants'&#xD;
      stimulant use disorder will be targeted through contingency management, with twice weekly&#xD;
      urine drug screens and monetary prizes in exchange for negative urine drug screens. Through&#xD;
      regular clinic visits and the use of incentives, the investigators hope to increase treatment&#xD;
      adherence and increase the number of negative urine drug screens in subjects struggling with&#xD;
      co-morbid opioid use disorder and stimulant use disorder. The investigators will determine&#xD;
      whether or not this treatment is effective in this population, versus conventional treatment&#xD;
      (baseline therapy patients were getting through OBOT). The investigators' primary outcome&#xD;
      measure will be stimulant abstinence duration during the twelve week study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>stimulant abstinence</measure>
    <time_frame>12 weeks</time_frame>
    <description>Duration of stimulant abstinence based on urine drug screens</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Stimulant Use</condition>
  <condition>Contingency Management</condition>
  <arm_group>
    <arm_group_label>Contingency management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will include data from participants who received CM</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Contingency Management</intervention_name>
    <description>Contingency management involves receiving monetary prizes in exchange for negative urine drug screens.</description>
    <arm_group_label>Contingency management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 and older&#xD;
&#xD;
          -  Patients treated for opioid use disorder in the Outpatient Based Opioid Treatment&#xD;
             (OBOT) Clinic and who also struggle with stimulant use disorder but failed&#xD;
             conventional treatment (positive urine drug screen for substances other than THC and&#xD;
             buprenorphine)&#xD;
&#xD;
          -  Ideal candidates will test positive for 3 out of 4 weeks or more prior to starting&#xD;
             contingency management&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persons under the age of 18&#xD;
&#xD;
          -  Persons not able to attend follow-up clinic visits&#xD;
&#xD;
          -  Persons not able to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nassima Ait-Daoud Tiouririne, MD</last_name>
    <phone>(434)243-0563</phone>
    <email>NAT7B@hscmail.mcc.virginia.edu</email>
  </overall_contact>
  <results_reference>
    <citation>Ginley MK, Pfund RA, Rash CJ, Zajac K. Long-term efficacy of contingency management treatment based on objective indicators of abstinence from illicit substance use up to 1 year following treatment: A meta-analysis. J Consult Clin Psychol. 2021 Jan;89(1):58-71. doi: 10.1037/ccp0000552.</citation>
    <PMID>33507776</PMID>
  </results_reference>
  <results_reference>
    <citation>McPherson SM, Burduli E, Smith CL, Herron J, Oluwoye O, Hirchak K, Orr MF, McDonell MG, Roll JM. A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies. Subst Abuse Rehabil. 2018 Aug 13;9:43-57. doi: 10.2147/SAR.S138439. eCollection 2018. Review.</citation>
    <PMID>30147392</PMID>
  </results_reference>
  <results_reference>
    <citation>Miguel AQ, Madruga CS, Cogo-Moreira H, Yamauchi R, Sim√µes V, da Silva CJ, McPherson S, Roll JM, Laranjeira RR. Contingency management is effective in promoting abstinence and retention in treatment among crack cocaine users in Brazil: A randomized controlled trial. Psychol Addict Behav. 2016 Aug;30(5):536-543. Epub 2016 Jul 21.</citation>
    <PMID>27442691</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Nassima Ait-Daoud Tiouririne</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

